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Abstract
Background: Monitoring of the uptake and efficacy of ART in a population often relies on cross-sectional data, providing
limited information that could be used to design specific targeted intervention programs. Using repeated measures of viral
load (VL) surveillance data, we aimed to estimate and characterize the proportion of persons living with HIV/AIDS (PLWHA)
in New York City (NYC) with sustained high VL (SHVL) and durably suppressed VL (DSVL).
Methods/Principal Findings: Retrospective cohort study of all persons reported to the NYC HIV Surveillance Registry who
were alive and $12 years old by the end of 2005 and who had $2 VL tests in 2006 and 2007. SHVL and DSVL were defined
as PLWHA with 2 consecutive VLs $100,000 copies/mL and PLWHA with all VLs #400 copies/mL, respectively. Logistic
regression models using generalized estimating equations were used to model the association between SHVL and
covariates. There were 56,836 PLWHA, of whom 7% had SHVL and 38% had DSVL. Compared to those without SHVL,
persons with SHVL were more likely to be younger, black and have injection drug use (IDU) risk. PLWHA with SHVL were
more likely to die by 2007 and be younger by nearly ten years, on average.
Conclusions/Significance: Nearly 60% of PLWHA in 2005 had multiple VLs, of whom almost 40% had DSVL, suggesting
successful ART uptake. A small proportion had SHVL, representing groups known to have suboptimal engagement in care.
This group should be targeted for additional outreach to reduce morbidity and secondary transmission. Measures based on
longitudinal analyses of surveillance data in conjunction with cross-sectional measures such as community viral load
represent more precise and powerful tools for monitoring ART effectiveness and potential impact on disease transmission
than cross-sectional measures alone.
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Introduction
Surveillance data with expanded HIV-related lab reporting can
be used to monitor the HIV epidemic and inform community-
wide HIV prevention, care, and treatment efforts. High HIV viral
load (VL) among HIV-infected persons is associated with clinical
progression to AIDS and death and increased risk for secondary
transmission to sex- and needle- sharing partners.[1,2,3,4]
Durable virologic suppression, achieved by initiation of highly
active antiretroviral therapy (HAART) and engagement in regular
HIV-medical care, is necessary to restore immune status, increase
survival, and reduce risk of transmission to HIV-uninfected
partners. [5,6,7,8] Until recently, surveillance systems did not
collect data related to the care and treatment of HIV/AIDS. HIV-
related laboratory results like VL, CD4 counts, and genotype
testing, now reportable to public health departments in many
areas of the US, serve as surrogate markers of linkage to and
retention in HIV-related medical care.[9,10] Such longitudinal
data are a source of the type of population-based indicators that
have long been desired by HIV policymakers.[11] Furthermore,
the Centers of Disease Control (CDC)-led community trials
underway in Washington, DC, the New York City borough of the
Bronx, Chicago, Houston, Miami, and Philadelphia, use HIV
surveillance data to evaluate the feasibility of an enhanced test-
and-treat strategy (‘‘TLC-Plus’’), which aims to prevent new HIV
infections through expanding treatment coverage, improving HIV
testing rates and linkage to and retention in HIV care.[12] TLC-
Plus and other community-level initiatives rely on HIV-related
laboratory reporting to measure and reduce community viral load,
an action recommended by the National HIV/AIDS Strategy
(NHAS) as part of its larger goal to eliminate HIV-related health
disparities.[13]
Recently-published analyses of VL data reported to municipal
HIV surveillance systems values have utilized a novel, ecologic
measure, community viral load (CVL), as an efficient means of
summarizing treatment effectiveness and assessing the success of
test-and-treat strategies in a population. In analyses in San
Francisco and British Columbia, lower CVL has been shown to
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diagnoses.[14,15] While CVL is an appropriate summary measure
that provides an overall snapshot of a dynamic cohort, the
measure is based on a serial cross-sectional design that limits the
ability to make causal inferences on transmission because viral
load results cannot be linked back to a given individual.[14] A high
CVL may not equate to high VL burden in a particular group as
VLs can vary depending on treatment status and risk behaviors at
the individual and group-level. Estimates based on repeated VL
measures over time may better identify groups with high VL
burden as they represent persons with sustained high viremia.
However, estimates from both serial cross-sectional and longitu-
dinal analyses are complementary. CVL has the potential to
identify high-risk groups that may need additional prevention
efforts, while longitudinal estimates help decipher what underlies
the CVL, summarizing the dynamics of control of VL at the
individual and group level. Taken together, these measures may
help target HIV care and treatment interventions to the
subpopulations whose viral control – if achieved - will most likely
result in rapid lowering of CVL.
The current analysis extends CVL analyses by using longitu-
dinal data to define novel summary measures in an HIV-infected
population: Sustained high viral load (SHVL), and durably-
suppressed viral load (DSVL). We used these measures to evaluate
community-wide control of HIV viremia in NYC in 2006–2007,
and to identify factors associated with SHVL, with the hypothesis
that SHVL is more common among groups known to have
suboptimal engagement in HIV-related medical care.
Methods
Ethics Statement
Data were collected as part of legally-mandated public health
surveillance for HIV in New York State, according to Chapter 163
of New York State Public Health Law, Article 21, Title 3. Analysis
of HIV surveillance data is authorized for the purpose of
epidemiologic monitoring, as specified in the New York Codes,
Rules and Regulations, Title 10, Part 63 (Revised 6/2005). This
analysis, using existing and de-identified data, qualifies as non-
research according to the Department of Health and Human
Services (DHHS) regulations for the protection of human rights in
45 CFR 146.102[d]. For these reasons, this analysis is exempt
from human subjects review requirements.
Data Sources
The NYC HIV Surveillance Registry (Registry) is a population-
based registry of all persons diagnosed with HIV infection or
AIDS, as defined by the CDC, and reported to the NYC
DOHMH.[16] Name-based reporting of AIDS diagnoses was
mandated by New York State (NYS) law in 1983, followed by HIV
reporting in 2000 and laboratory reporting of all positive Western
Blots, viral loads, CD4 counts, and nucleotide sequence results in
2005.[17] All incoming electronic laboratory reports are matched
to cases in the Registry.[10] Vital status for all cases in the Registry
is updated through quarterly matches to the NYC Death Registry
and periodic matches to national death data. Data for this analysis
were reported to the NYC DOHMH as of December 31, 2009.
Eligibility criteria
All persons diagnosed with HIV infection reported to the NYC
DOHMH by December 31, 2009 and presumed to be living with
HIV/AIDS as of the end of December 2005 were eligible for
inclusion. Cases that were at least 12 years of age by December 31,
2005, had a NYC residence at HIV or first-AIDS diagnosis, and
had two or more HIV RNA viral load tests reported between
January 1, 2006 and December 31, 2007 were included in the
analysis. VLs reported less than two weeks apart for the same
individual were censored to maximize the possibility that VL
values represented a deliberate attempt to monitor clinical status
with serial measurements rather than tests repeated for quality
control or other reasons.
Analytic Variables
Outcome variables. HIV VL results were quantified using
VL testing kits that were commercially-available and in use in
NYC at the time. Results were reported as a continuous value or
as the limit of detection of the testing kit used. Three analytic and
mutually exclusive variables were constructed for each individual:
Peak VL, SHVL, and DSVL. For descriptive analyses, peak VL
was defined as the maximum VL value observed for an individual
between January 1, 2006 and December 31, 2007. Peak VLs were
categorized into three groups: 1) Undetectable: 0 to #400 copies/
mL; 2) Other: 401 to 99,999 copies/mL); and 3) High: $100,000
copies/mL. For descriptive analyses, SHVL was defined as an
individual ever having a pair of consecutive VLs $100,000
copies/mL. To measure the duration of SHVL, we defined SHVL
in statistical models as a proportion, the number of consecutive VL
pairs $100,000 copies/mL out of total pairs observed. An interval
was defined as the difference in time between the first and second
test dates within a pair of consecutive VLs.
Independent variables. Analytic variables included HIV
transmission risk, age, race/ethnicity, sex, borough of residence,
history of an AIDS diagnosis, and presence of concurrent AIDS at
the time of HIV diagnosis. We applied the CDC hierarchy to
create transmission risk categories to guide risk assignment,
especially for cases with more than one reported risk.[18]
Transmission risk categories included injection drug use (IDU),
men who have sex with men (MSM), heterosexual sex, and other.
Heterosexual risk included persons who reported having
heterosexual sex with an HIV-infected person, an IDU, or a
person who had received blood products. For females only,
heterosexual risk also included sex with a male and at least one of
the following: history of commercial sex work, multiple male sex
partners, sexually transmitted disease, crack/cocaine, sex with a
bisexual male, probable heterosexual transmission as noted in a
medical chart, or negative history of IDU. Other risk included
persons with perinatal, transfusion, transplant, and unknown risk.
Covariates. Age was defined as the difference in years
between date of birth and December 31, 2005. Race/ethnicity
Figure 1. Eligibility flow chart on HIV-infected New Yorkers,
2006 and 2007.
doi:10.1371/journal.pone.0029679.g001
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white and ‘other.’ Persons of Hispanic ethnicity, regardless of race,
were classified as Hispanic. Due to small numbers, Asian/Pacific
Islanders, Native Americans, and persons reporting multiple, other
or unknown race were grouped as ‘Other.’ Borough, which
designates the five county geography of NYC, referred to the
borough of residence at the time of HIV or AIDS diagnosis. Time
since diagnosis was treated as a binary variable, with a cutoff at 5
years, representing the 25
th percentile of infection times, defined as
the difference from date of diagnosis to December 31, 2005.
Table 1. Characteristics of HIV-infected New Yorkers with $2 viral load tests and all persons diagnosed and presumed living, New
York City
1.
Characteristic Subcategory
PLWHA
with $2 tests
N( % )
All PLWHA
as of 12/2005
N( % )
Overall 56,836 98,704
Risk
2
MSM 17,076 (30) 29,559 (30)
IDU 12,624 (22) 22,703 (23)
Other/Unknown 15,520 (27) 28,422 (29)
Heterosexual 11,616 (20) 17,887 (18)
Age in years
Mean (Med) 44 (44) 44 (44)
Sex
Female 18,661 (33) 29,920 (30)
Male 38,175 (67) 68,651 (70)
Race/ethnicity
3
Non-Hispanic Black 26,214 (46) 44,310 (45)
Non-Hispanic White 11,121 (20) 20,543 (21)
Hispanic 19,177 (34) 31,812 (33)
Other 324 (,1) 802 (,1)
Borough of residence
4
Bronx 14,105 (25) 21, 409 (22)
Brooklyn 15,291 (27) 24,376 (25)
Manhattan 18,638 (33) 29,807 (30)
Queens 7,752 (14) 13,596 (14)
Staten Island 1,050 (2) 1,780 (,2)
Outside of NYC 0 7,589 (8)
Unknown/Missing 0 14 (,1)
Concurrent HIV/AIDS diagnosis
Yes 13,359 (24) 25,246 (26)
No 43,477 (76) 73,458 (74)
Time since diagnosis in years
Mean (Median) 8 (7) 8 (7)
AIDS as of 2005
N (%) 21,978 (62) 59,486 (60)
Time since AIDS in years
Mean (Median) 6 (6) 7 (7)
VL tests from 2006 to 2007
Mean (Median) 6 (6) 5 (5)
VL, viral load. NYC, New York City. PLWHA, persons living with HIV/AIDS. MSM, men who have sex with men. IDU, intravenous drug users.
1Data as reported to the NYC DOHMH by December 31, 2009.
2Includes persons who had heterosexual sex with an HIV-infected person, an injection drug user, or a person who has received blood products. For females only,
heterosexual sex also includes sex with a male and at least one of the following: history of commercial sex work, multiple male sex partners, sexually transmitted
disease, crack/cocaine use, sex with a bisexual male, probable heterosexual transmission as noted in a medical chart, or negative history of injection drug use.
3NYC DOHMH collects race and ethnicity data that meet federal standards of classification and maintains ethnicity data separately from race information. Persons of
Hispanic or Latino ethnicity have a separate race classification. Due to small numbers, persons reporting more than one race, Native Americans or Alaska Natives,
Hawaiian Natives, Asian, and Pacific Islanders were classified as ‘Other’.
4Borough of residence refers to the residence at HIV diagnosis for persons living with HIV (non-AIDS) or residence at AIDS diagnosis for PLWHA.
doi:10.1371/journal.pone.0029679.t001
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The population analyzed was compared to all PLWHA in the
Registry as of December 31, 2005 to assess whether there were
differences by sociodemographic characteristics. Within the
population analyzed, comparisons were made between individuals
with SHVL and DSVL. All comparisons were tested using x
2 tests
of association. Marginal mean models were specified, relating the
response variable, SHVL, to covariates and the working
correlation structure between the probabilities of SHVL at
different time points, using generalized estimating equations
(GEE) methods.[19] In multivariate models, estimates were
adjusted for age, race/ethnicity, sex, borough of residence,
concurrent HIV/AIDS status, and time since diagnosis. SAS
v9.2 software was used to conduct the analysis (SAS Institute Inc.,
Cary, NC).
Results
The population analyzed included 56,836 PLWHA, represent-
ing nearly 60% of all PLWHA diagnosed and presumed living in
NYC at the end of 2005 (Figure 1). PLWHA with $2 VLs were
demographically similar to all PLWHA at the end of 2005
(Table 1). Two-thirds of PLWHA with $2 VLs were male and
nearly one-third had a reported MSM risk. Nearly one-quarter
had IDU risk. The proportion concurrently diagnosed with HIV
and AIDS was 24%. Nearly two-thirds had an AIDS diagnosis by
the end of 2005. Almost 40% had DSVL, meaning all VLs were
#400 copies/mL. Fifteen percent had a peak VL $100,000
copies/mL (N=8,403). Among those with a high peak VL, 52%
had a VL $100,000 only once in the two years and 40%
(N=4,210) had SHVL, meaning at least two consecutive VLs
$100,000 (Figure 2). Compared to all PLWHA, those with SHVL
were slightly younger (median age 42 vs.44 years), more likely to
be non-Hispanic black (50% vs. 45%), female (36% vs. 30%), and
have a higher median number of tests (7 vs. 5; Table 2). They were
also more likely to have died by the end of 2007 (11% vs. 3%;
Table 2) and at a younger age, nearly 10 years younger, than those
without SHVL (data not shown). Among those who died, the
proportion with IDU risk in the SHVL and DSVL groups was
35% and 45%, respectively.
Table 3 summarizes estimates from univariate and multivariate
GEE regression models. IDU risk remained significantly associated
with SHVL compared to heterosexual risk, after adjusting for age,
sex, race, borough of residence, concurrent HIV/AIDS status, and
time since diagnosis (adjusted odds ratio [AOR]=1.34; 95%
Confidence Interval [CI]=1.19,1.50). MSM had significantly
decreased risk for SHVL compared with heterosexuals. Compared
with persons aged 50+, all younger age groups were at increased
risk for SHVL, though the youngest group were at highest risk
(AOR=3.42; 95% CI=2.72, 4.32).
Non-Hispanic blacks and Hispanics were 46% and 29% more
likely to have SHVL than whites, respectively (AOR=1.46; 95%
CI=1.30,1.65; AOR=1.29; 95% CI=1.14, 1.46). PLWHA with
concurrent HIV/AIDS at diagnosis were 11% more likely than
those without concurrent diagnosis to have SHVL (AOR=1.11;
95% CI=1.02, 1.21). Bronx residents were 13% more likely to
have SHVL than Manhattan residents (AOR=1.13; 95%
CI=1.02, 1.25). No significant associations were observed
between SHVL and sex or time since diagnosis.
Discussion
We used public health HIV surveillance data to create novel
summary measures that track HIV VL dynamics at the population
level, and applied these longitudinal measures to the known
population of HIV-infected New Yorkers receiving HIV-related
medical care in NYC in 2006 and 2007. Findings show that
analytic population had an average of six VL test results,
suggesting frequent engagement in HIV-related medical care.
Almost 40% had virologic suppression for two years, indicating
sustained treatment success.
Previous studies have shown that IDUs and persons of color
were more likely to delay initiation and have inconsistent
utilization of HIV-related care compared to non IDUs and non-
Hispanic whites in NYC.[9,10] Findings that show IDUs, blacks,
and Hispanics at increased risk for SHVL support our hypothesis
that SHVL is more common among groups known to have
suboptimal engagement in HIV-related medical care. IDUs face
challenges in achieving timely linkage to and retention in
care.[20–25] Delayed initiation of care is associated with poorer
immunologic recovery and increased risk of death.[8,10,26] Our
analysis suggests that IDUs are an appropriate focus for public
health programs aimed at increasing engagement in care among
groups most at-risk for HIV-related morbidity.
Blacks, accounting for more than half of PLWHA in the US and
with HIV diagnosis rates 8 times that of whites, are also more
likely to delay initiation of care after HIV diagnosis.
[8,10,27,28,29] Hispanics, accounting for 17% of all new HIV
infections in 2006 and with HIV diagnosis rates 3 times that of
whites, have similar barriers to engagement in care. [30,31] This
trend is consistent with the NYC epidemic where blacks and
Hispanics accounted for 50% and 33% of all newly diagnosed
Figure 2. HIV-infected New Yorkers grouped by VL trend, 2006–2007.
doi:10.1371/journal.pone.0029679.g002
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all persons diagnosed and presumed living, New York City
1.
Characteristic Subcategory
Sustained high viral load
N( % )
Durably suppressed
N( % )
All PLWHA as of 12/05
N( % )
Overall 4,210 21,960 98,704
Risk
2
MSM 1,058 (25) 7,592 (35) 29,556 (30)
IDU 1,113 (26) 4,104 (19) 22,616 (23)
Other/Unknown 1,144 (27) 5,981 (27) 26,297 (29)
Heterosexual 895 (21) 4,283 (20) 17,780 (18)
Age in years
Mean (Med) 41 (42) 47(46) 44 (44)
IQR 36, 47 40, 53 38, 51
Sex
Female 1,502 (36) 6,562 (30) 29,973 (30)
Race/ethnicity
3
Non-Hispanic Black 2,141 (50) 8,998 (40) 44,478 (45)
Non-Hispanic White 585 (14) 5,492 (25) 20,617 (21)
Hispanic 1,473 (35) 7,321(33) 31,715 (32)
Other 11 (,2) 149 (2) 1,894 (,2)
Borough of residence
4
Bronx 1,202 (29) 4,667 (21) 21, 409 (22)
Brooklyn 1,196 (28) 5,517 (25) 24,376 (25)
Manhattan 1,247 (30) 7,981 (36) 29,807 (30)
Queens 488 (11) 3,402 (16) 13,596 (14)
Staten Island 77 (2) 3jk93 (2) 1,780 (,2)
Outside of NYC 0 0 7,589 (8)
Unknown/Missing 0 0 14 (,1)
Concurrent HIV/AIDS at diagnosis
Yes 1,021 (24) 6,260 (29) 26,279 (27)
No 3,189 (76) 15,700 (71) 72,427 (74)
Time since diagnosis in years
Mean (Median) 9 (8) 9 (8) 8 (7)
IQR 5, 13 5, 12 4, 12
AIDS as of 12/05
N (%) 3,123 (74) 14,236 (65) 59,492 (60)
Time since AIDS in years
Mean (Median) 6 (6) 7 (7) 7 (7)
Deaths as of 12/07
N (%) 481 (11) 464 (2) 2,545 (3)
VL tests, 2006–2007
Mean (Median) 7 (7) 6 (6) 5 (5)
VL, viral load. NYC, New York City. PLWHA, persons living with HIV/AIDS. MSM, men who have sex with men. IDU, intravenous drug use. IQR, interquartile range. NA, not
available.
1Data as reported to the NYC DOHMH by December 31, 2009.
2Includes persons who had heterosexual sex with an HIV-infected person, an injection drug user, or a person who has received blood products. For females only,
heterosexual sex also includes sex with a male and at least one of the following: history of commercial sex work, multiple male sex partners, sexually transmitted
disease, crack/cocaine use, sex with a bisexual male, probable heterosexual transmission as noted in a medical chart, or negative history of injection drug use.
3NYC DOHMH collects race and ethnicity data that meet federal standards of classification and maintains ethnicity data separately from race information. Persons of
Hispanic or Latino ethnicity have a separate race classification. Due to small numbers, persons reporting more than one race, Native Americans or Alaska Natives,
Hawaiian Natives, Asian, and Pacific Islanders were classified as ‘Other’.
4Borough of residence refers to the residence at HIV diagnosis for persons living with HIV (non-AIDS) or residence at AIDS diagnosis for PLWHA.
doi:10.1371/journal.pone.0029679.t002
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marker of late-stage disease and missed opportunities for care.[32]
MSM, disproportionately accounting for prevalent and new
diagnoses in NYC, have been shown to have timely initiation and
high retention in HIV-related medical care, often serving as the
referent group for studies on linkage to care.[9,10,33] Because
engagement in care dramatically improves the probability of
achieving virologic suppression, it is not surprising that MSM were
over-represented among those with DSVL and were not at
increased risk for SHVL in this analysis. While blacks and
Hispanics comprise less than 60% of MSM overall, they made up
almost 90% of MSM with SHVL. Future analyses on SHVL
exploring the interaction of transmission risk and race/ethnicity
and other markers of SES such as proportion living below poverty,
Table 3. Univariate and multivariate GEE regression models identifying factors associated with sustained high viral load in 2006–
2007, New York City (N=56,836)
1.
Characteristic Subcategory
PLWHA with $2t e s t s
N( % )
Crude OR
(95% CI)
2
Adjusted OR
(95% CI)
2,3
Risk
4
MSM 17,076 (30) 0.74 (0.66, 0.82) 0.80 (0.70, 0.91)
IDU 12,624 (22) 1.16 (1.04, 1.29) 1.34 (1.19, 1.50)
Other 15,520 (27) 1.02 (0.92, 1.13) 1.00 (0.90, 1.12)
Heterosexual 11,616 (20) 1.00 1.00
Age
13–19 1,038 (,2) 3.56 (2.85, 4.46) 3.42 (2.72, 4.32)
20–29 3,438 (6) 2.48 (2.12, 2.89) 3.09 (2.63, 3.63)
30–39 12,175 (21) 2.48 (2.22, 2.70) 2.86 (2.56, 3.19)
40–49 23,240 (41) 1.92 (1.74, 2.12) 2.02 (1.80, 2.24)
$50 16,945 (30) 1.00 1.00
Sex
Female 18,661 (33) 1.20 (1.12, 1.30) 0.95 (0.87, 1.04)
Male 38,175 (67) 1.00 1.00
Race/ethnicity
5
Non-Hispanic Black 26,214 (46) 1.78 (1.60, 2.00) 1.46 (1.30, 1.65)
Hispanic 19,177 (34) 1.67 (0.48, 1.88) 1.29 (1.14, 1.46)
Other 324 (,1) 0.70 (0.36, 1.36) 0.71 (0.37,1.37)
Non-Hispanic White 11,121 (20) 1.00 1.00
Borough of residence
6
Bronx 14,105 (25) 1.41 (1.28, 1.55) 1.13 (1.02, 1.25)
Brooklyn 15,291 (27) 1.24 (1.13,1.36) 1.04 (0.94, 1.14)
Queens 7,752 (14) 0.98 (0.86, 1.11) 0.87 (0.76, 0.98)
Staten Island 1,050 (2) 1.21 (0.92, 1.59) 1.15 (0.88, 1.50)
Manhattan 18,638 (33) 1.00 1.00
Concurrent HIV/AIDS at diagnosis
Yes 13,359 (24) 1.05 (0.96, 1.14) 1.11 (1.02, 1.21)
No 43,477 (76) 1.00 1.00
Time since diagnosis in years
0–4 17,225 (30) 1.04 (0.96, 1.12) 0.93 (0.85, 1.01)
$5 39,661 (70) 1.00 1.00
GEE, generalized estimating equations. VL, viral load. MSM, men who have sex with men. IDU, intravenous drug users.
1Data as reported to the NYC DOHMH by December 31, 2009.
2Adjusted for number of VL pairs observed, 2006–2007.
3Adjusted for age, race/ethnicity, borough, sex, history of AIDS, concurrent HIV/AIDS status at diagnosis, and number of pairs of VL tests.
4Heterosexual risk includes persons who had heterosexual sex with an HIV-infected person, an injection drug user, or a person who has received blood products. For
females only, heterosexual sex also includes sex with a male and at least one of the following: history of commercial sex work, multiple male sex partners, sexually
transmitted disease, crack/cocaine use, sex with a bisexual male, probable heterosexual transmission as noted in a medical chart, or negative history of injection drug
use.
5NYC DOHMH collects race and ethnicity data that meet federal standards of classification and maintains ethnicity data separately from race information. Persons of
Hispanic or Latino ethnicity have a separate race classification. Due to small numbers, persons reporting more than one race, Native Americans or Alaska Natives,
Hawaiian Natives, Asian, and Pacific Islanders were classified as ‘Other.’
6Borough of residence refers to the residence at HIV diagnosis for persons living with HIV (non-AIDS) or residence at AIDS diagnosis for persons living with AIDS.
doi:10.1371/journal.pone.0029679.t003
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population at increased risk for SHVL.
Bronx residents were at increased risk for SHVL, a finding
consistent with other HIV indicators showing increased HIV-
related morbidity and mortality in the Bronx compared to the
other boroughs. [34] Bronx residence is likely a surrogate marker
for other group membership like race/ethnicity and transmission
risk. Known health disparities in the Bronx were part of the
impetus for the selection of the Bronx for the DOHMH’s
community-wide HIV testing scale-up effort, ‘‘The Bronx
Knows’’. [35]
One of the most concerning findings was that PLWHA aged
13–19 years had 3 times greater risk of SHVL than PLWHA 50
years or older. The relative youth of the 13–19 years age group
belies the likelihood that most are highly ART-experienced, given
that more than 80% of them were infected with HIV through
perinatal transmission, and were diagnosed during the era of
mono and dual therapy before highly active antiretroviral
regimens were available for HIV treatment. The SHVL among
these perinatally-infected adolescents may stem from the develop-
ment of ART resistant viral strains, or from the adherence gaps
often observed among adolescents with chronic illnesses. [36,37]
Regardless of its causes, the presence of SHVL among PLWHA
who have entered their sexually-active and childbearing years has
serious implications for HIV transmission. HIV-infected youth
often engage in unprotected sex and do not disclose their HIV
status to sex partners. [38,39] HIV-infected youth are also more
likely to have a diagnosis of an acute sexually transmitted infection
than HIV-infected adults and, among females, to become
pregnant. [40] SHVL concomitant with risky sexual behaviors
places youth at higher risk for HIV-related morbidity and
transmitting to others.
Our analysis is subject to limitations. Findings are based on
persons presumed to be in care because they had VL results
reported to the NYC DOHMH. More than one third of nearly
100,000 PLWHA reported by the end of 2005 were excluded
because they had only one or no VL result reported in 2006–2007.
This group may represent persons who: 1) are receiving HIV care
outside of NYC; 2) died out of NYC and their death was not yet
reported to the NYC DOHMH; 3) are out of care; or 4) received
care but not VL testing. Because the HIV-infected population in
the US is highly mobile and PLWH relocation to jurisdictions
outside of NYC are not routinely reported to DOHMH, it is
difficult to estimate the proportion of NYC PLWHA without a
recent viral load who are engaged in care in another reporting
jurisdiction. Despite this distinction, no differences by socio-
demographic characteristics between PLWHA with 2 or more VLs
and all PLWHA were observed (Table 1). [41]
Characterization of the ‘other’ group where peak VL was
detectable but never $100,000 copies/mL was limited. Given the
heterogeneity in infection times and treatment experiences, some
PLWHA may have a more difficult-to-treat virus where achieving
DSVL is unlikely with any level of adherence, and thus cannot be
considered the goal of therapy. Refinement of the characterization
of HIV viremia in this group by exploring measures like area
under the curve (AUC), a commonly used measure to quantify rate
of change in biomarkers over time, may provide a more
comprehensive measure. [42,43]
Our ability to infer the level of engagement in care from the
number of cumulative VL tests may be limited. We assumed that
1) those more engaged in care had a higher cumulative number of
VL tests and; 2) those with the same cumulative number of tests
were similar in their access and utilization of care. However, those
with the same number of VL tests may be quite different. Among
persons with fewer VL tests, for example, some may be non-
adherent, experiencing virologic failure and missing the visits at
which their VLs would be drawn, while others may be durably
suppressed on a stable ART regimen, and therefore require less
frequent clinical monitoring. Lastly, VL tests do not necessarily
mean that meaningful HIV care was provided to the person tested
by a qualified HIV clinician, or that results were received and
informed treatment.[33]
Our analyses show that DSVL and SHVL detected HIV
disparities, similar to more established HIV population indicators
like HIV incidence, diagnosis, and death rates. [44] Because
undetectable VL is associated with reduced transmission and
improved health outcomes, achieving suppression, a specific target
of the NHAS, necessitates use of longitudinal measures. [45–47]
Our markers not only complement CVL as basic measures of
treatment coverage and effectiveness, but improve measurement
by characterizing longitudinal patterns of VL dynamics within a
population. Moreover, identifying SHVL provides a specific
opportunity for outreach to those HIV-infected individuals in a
community who are at greatest risk of near-term HIV-related
morbidity and mortality. In 2011, DOHMH began active
outreach among persons with SHVL who appeared to lack
medical follow-up in the months that followed their very high viral
load, with the goal of interviewing these clients about partner
services and assisting them with returning to medical care for HIV.
Prior to this analysis, such outreach was not specifically directed or
prioritized based on the magnitude of HIV VL prior to
interruption of care. Future analyses will 1) characterize longer-
term trajectories of persons with SHVL and DSVL, using AUC to
help distinguish rates of virologic change particularly among those
with the same number of tests, 2) characterize genotype profiles
among SHVLs and measure the proportion who have resistant
strains and 3) investigate the relationship between the number of
newly reported HIV diagnoses and number of PLWHA with
SHVL and DSVL to evaluate its potential as a surrogate marker of
incidence. Altogether, findings support the use of these surveil-
lance markers to evaluate treatment effectiveness and HIV
transmission risk, especially in high risk groups.
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